Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neumora Therapeutics (NMRA) Change in Acquisitions & Divestments (2022 - 2024)

Neumora Therapeutics' quarterly Change in Acquisitions & Divestments came in at $36.6 million in Q1 2024, down 17.5% year-on-year from $44.3 million in Q2 2023, and down 4.7% quarter-over-quarter from $38.4 million in Q4 2023.

Neumora Therapeutics has reported Change in Acquisitions & Divestments for 3 years, with the latest figure at $36.6 million in Q1 2024.

  • For the quarter ending Q1 2024, Change in Acquisitions & Divestments fell 17.5% year-over-year to $36.6 million; the trailing twelve-month figure through Mar 2024 stood at $159.4 million (changed N/A YoY), and the FY2023 full-year result was $178.2 million, up 147.91% from the prior year.
  • Change in Acquisitions & Divestments for Q1 2024 stood at $36.6 million, down from $38.4 million in the prior quarter.
  • The five-year high for Change in Acquisitions & Divestments was $44.3 million in Q1 2023, with the low at $36.6 million in Q1 2024.
  • Average Change in Acquisitions & Divestments over 3 years is $39.8 million, with a median of $39.2 million recorded in 2022.
  • Year-over-year, Change in Acquisitions & Divestments slipped 4.25% in 2023 and dropped 17.5% in 2024.
  • Tracing NMRA's Change in Acquisitions & Divestments over 3 years: stood at $40.1 million in 2022, then slipped by 4.25% to $38.4 million in 2023, then dropped by 4.7% to $36.6 million in 2024.
  • The last three Change in Acquisitions & Divestments figures came in at $36.6 million (Q1 2024), $38.4 million (Q4 2023), and $44.3 million (Q1 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Neumora Therapeutics 328.27 Mn 328.27 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2024 36.58 Mn
Mar 31, 2024 36.58 Mn
Dec 31, 2023 38.38 Mn
Dec 31, 2023 38.38 Mn
Mar 31, 2023 44.34 Mn
Mar 31, 2023 44.34 Mn
Dec 31, 2022 40.09 Mn
Dec 31, 2022 40.09 Mn